Transdermal fentanyl in children with cancer pain: Feasibility, tolerability, and pharmacokinetic correlates

Journal of Pediatrics

Volumn 134, Issue 3, 1999, Pages 319-323

  Collins, John J ^a,b,c,d,e   Dunkel, Ira J ^a,b,c,d   Gupta, Suneel K ^a,b,c,d   Inturrisi, Charles E ^a,b,c,d   Lapin, Jeanne ^a,b,c,d   Palmer, Leah N ^a,b,c,d   Weinstein, Sharon M ^a,b,c,d   Portenoy, Russell K ^a,b,c,d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Cornell University ^*  (United States)

^d ALZA CORPORATION   (United States)

^e CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL;

ADOLESCENT; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG TOLERABILITY; HUMAN; PEDIATRIC ANESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

EID: 0033499792     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(99)70457-9     Document Type: Article

References (12)

1. 1. Sandler A. Transdermal fentanyl: acute analgesic clinical studies. J Pain Symptom Manage 1992;7:S27-35.
2. 2. Gourlay GK, Kowalski SR, Plummer JL, Cherry DA, Gaukroger P, Cousins MJ.he transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects. Pain 1989:37:193-202.
3. 3. Herbst LH, Strause LG. Transdermal fentanyl use in hospice home-care patients with chronic cancer pain. J Pain Symptom Manage 1992;7:S54-7.
4. 4. Maves TJ, Barcellos WA. Management of cancer pain with transdermal fentanyl: phase IV trial, University of Iowa. J Pain Symptom Manage 1992; 7:S58-62.
5. 5. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-fentanyl Comparative Trial Group. J Pain Symptom Manage 1997;13:254-61.
6. 6. Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998:16:1588-93.
7. 7. Gupta SK, Southam M, Gale R. System functionality and physiochemical model of fentanyl transdermal system. J Pain Symptom Manage 1992;7: S17-26.
8. 8. Gupta SK, Yih B, Bernstein K. Population analysis to evaluate dose proportionality of the transdermal fentanyl system. Clin Pharm Ther 1995;57:180.
9. 9. Berde C, Ablin A, Glazer J, Miser A, Shapiro B, Weisman S, et al. American Academy of Pediatrics Report of the Subcommittee on Disease-Related Pain in Childhood Cancer. Pediatrics 1990;86:818-25.
10. 10. Miser AW. Management of pain associated with childhood cancer. In: Schecter NL, Berde CB, Yaster M, editors. Pain in infants, children, and adolescents. Baltimore: Williams and Wilkins; 1993. p. 411-23.
11. 11. McGrath PJ, Beyer J, Cleeland C, Eland J, McGrath PA, Portenoy RK. American Academy of Pediatrics Report of the Subcommittee on Assessment and Methodologic Issues in the Management of Pain in Childhood Cancer. Pediatrics 1990;86:814-7.
12. 12. Portenoy RK, Southam MA, Gupta SK, Lapin J, Layman M, Inturissi CE, et al. Transdermal fentanyl for cancer pain. Anesthesiology 1993;78:36-43.